ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159

Evaluate recovery time on 2.5 mg/Kg/day dose of G-CSF versus 5 mg/Kg/day dose.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Peripheral Stem Cell/Marrow Transplant

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cross Cancer Institute

Edmonton, Alberta, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

over age 18
autologous stem cell/marrow transplant candidate in MM, lymphoma, AMG and testicular

Exclusion criteria

age below 18 years
sensitive to G-CSF

Treatment and study plan

G-CSF/Filgrastim

Drug

Sponsors and collaborators

Lead sponsor

Alberta Health services

Other

Registry information

Important dates

Study start: 2003
Study completion: 2007
First posted: Sep 15, 2005
Registry last updated: Feb 9, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.